35141-49-2 Usage
Heterocyclic compound
A compound containing a ring structure with at least one heteroatom, which is an atom other than carbon, such as nitrogen, oxygen, or sulfur.
Benzoxazine ring
A heterocyclic ring structure consisting of a benzene ring fused to an oxazine ring (a nitrogen-containing six-membered ring with alternating single and double bonds).
Chlorophenyl group
A phenyl group (a benzene ring) with a chlorine atom attached as a substituent.
Pharmaceutical applications
The potential use of the compound in the development of medications for treating various diseases or medical conditions.
Biological activities
The various effects the compound may have on biological systems, such as its ability to interact with proteins, enzymes, or cells.
Anti-inflammatory potential
The compound's ability to reduce inflammation, which may be useful in treating conditions characterized by excessive or unwanted inflammation.
Anti-cancer potential
The compound's ability to inhibit or prevent the growth and spread of cancer cells, making it a potential candidate for cancer treatment.
Medicinal chemistry
The field of chemistry focused on the design, synthesis, and development of new drugs and the study of their properties and interactions with biological systems.
Check Digit Verification of cas no
The CAS Registry Mumber 35141-49-2 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 3,5,1,4 and 1 respectively; the second part has 2 digits, 4 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 35141-49:
(7*3)+(6*5)+(5*1)+(4*4)+(3*1)+(2*4)+(1*9)=92
92 % 10 = 2
So 35141-49-2 is a valid CAS Registry Number.
35141-49-2Relevant articles and documents
Synthesis and anticonvulsant activity evaluation of 2-Phenyl-2H-benzo[e][1, 3]oxazin-4(3H)-ones
Cui, Li-Jing,Guo, Jun,Gong, Guo-Hua,Quan, Zhe-Shan
, p. 2553 - 2556 (2014/06/09)
A series of new 2-phenyl-2H-benzo[e][1,3]oxazin-4(3H)-one derivatives (1a-1t) were designed based on the known anticonvulsant activity of quinolinone derivatives. All target compounds 1a-1t, characterized by IR, 1H NMR and MS, have been evaluated for their anticonvulsant activity against MES-induced seizures. The pharmacological results showed that all the compounds displayed some degree of anticonvulsant activity. Among them, 2-phenyl-2,3-dihydrobenzo[e][1,3]oxazin-4-one (1a) and 2-(2-fluorophenyl)-2,3- dihydrobenzo-[e][1,3]oxazin-4- one (1b) were considerd more promising because of their lower ED50 (34.1 and 28.4 mg/kg) and higher protective index (11.1 and 8.0).
